Asset Details
Do you wish to reserve the book?
A randomized trial of adjunct testosterone for cancer‐related muscle loss in men and women
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A randomized trial of adjunct testosterone for cancer‐related muscle loss in men and women
Do you wish to request the book?
A randomized trial of adjunct testosterone for cancer‐related muscle loss in men and women
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A randomized trial of adjunct testosterone for cancer‐related muscle loss in men and women
2018
Overview
Background Cancer cachexia negatively impacts cancer‐related treatment options, quality of life, morbidity, and mortality, yet no established therapies exist. We investigated the anabolic properties of testosterone to limit the loss of body mass in late stage cancer patients undergoing standard of care cancer treatment. Methods A randomized, double‐blind, placebo‐controlled phase II clinical trial was undertaken to assess the potential therapeutic role of adjunct testosterone to limit loss of body mass in patients with squamous cell carcinoma of the cervix or head and neck undergoing standard of care treatment including chemotherapy and chemoradiation. Patients were randomly assigned in blocks to receive weekly injections of either 100 mg testosterone enanthate or placebo for 7 weeks. The primary outcome was per cent change in lean body mass, and secondary outcomes included assessment of quality of life, tests of physical performance, muscle strength, daily activity levels, resting energy expenditure, nutritional intake, and overall survival. Results A total of 28 patients were enrolled, 22 patients were studied to completion, and 21 patients were included in the final analysis (12 placebo, nine testosterone). Adjunct testosterone increased lean body mass by 3.2% (95% confidence interval [CI], 0–7%) whereas those receiving placebo lost 3.3% (95% CI, −7% to 1%, P = 0.015). Although testosterone patients maintained more favourable body condition, sustained daily activity levels, and showed meaningful improvements in quality of life and physical performance, overall survival was similar in both treatment groups. Conclusions In patients with advanced cancer undergoing the early phase of standard of care therapy, adjunct testosterone improved lean body mass and was also associated with increased quality of life, and physical activity compared with placebo.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Aged
/ Anorexia
/ Body Composition - drug effects
/ Cachexia
/ Cancer
/ Consent
/ Energy Metabolism - drug effects
/ Female
/ Head and Neck Neoplasms - complications
/ Head and Neck Neoplasms - diagnosis
/ Head and Neck Neoplasms - therapy
/ Humans
/ Male
/ Motor Activity - drug effects
/ Muscle
/ Muscle Strength - drug effects
/ Muscle, Skeletal - drug effects
/ Muscle, Skeletal - pathology
/ Muscle, Skeletal - physiopathology
/ Muscular Atrophy - drug therapy
/ Muscular Atrophy - metabolism
/ Muscular Atrophy - physiopathology
/ Original
/ Patients
/ Testosterone - therapeutic use
/ Women
